Clinical trial · Observational
Cardiac Magnetic Resonance for Early Detection of Chemotherapy or Radiation Therapy Induced Cardiotoxicity in Breast Cancer (CareBest)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Chemotherapy or radiation therapy-induced cardiotoxicity are well-recognized side effects in patients with cancer. The clinical significance of cardiotoxicity is growing with increasing cancer survivor-ship. Left ventricular (LV) functional assessment is the standard of reference to diagnose chemotherapy- or radiation therapy-induced cardiotoxicity. The investigators will investigate the usefulness of T1 mapping parameters for early detection and prediction of chemotherapy-, radiation therapy-, or other therapy-induced cardiotoxicity in breast cancer patients This study aimed to achieve early detection of chemotherapy- or radiation therapy-induced cardiotoxicity using T1 mapping magnetic resonance imaging (MRI) and determine a prognostic imaging factor of chemotherapy- or radiation therapy-induced cardiotoxicity in patients treated for breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Induced Cardiotoxicity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cardiac magnetic resonance imaging | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- label
- Control group
- interventionNames
- Other: Cardiac magnetic resonance imaging
- label
- Pretreatment group
- description
- Patients in pretreatment state
- interventionNames
- Other: Cardiac magnetic resonance imaging
- label
- Anthracycline-based chemotherapy (3 months)
- description
- Patients who received anthracycline-based chemotherapy 3 months ago
- interventionNames
- Other: Cardiac magnetic resonance imaging
- label
- Anthracycline-based chemotherapy (6 months)
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 17 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with breast cancer Exclusion Criteria: * Contraindication of MRI * Failure with informed consent * Fail to scan screening protocol
References
Publications (2)
- DERIVEDHong YJ, Han K, Lee HJ, Hur J, Kim YJ, Kim MJ, Choi BW. Assessment of Feasibility and Interscan Variability of Short-time Cardiac MRI for Cardiotoxicity Evaluation in Breast Cancer. Radiol Cardiothorac Imaging. 2024 Feb;6(1):e220229. doi: 10.1148/ryct.220229. PMID 38329404
- DERIVEDHong YJ, Kim GM, Han K, Kim PK, Lee SA, An E, Lee JY, Lee HJ, Hur J, Kim YJ, Kim MJ, Choi BW. Cardiotoxicity evaluation using magnetic resonance imaging in breast Cancer patients (CareBest): study protocol for a prospective trial. BMC Cardiovasc Disord. 2020 Jun 3;20(1):264. doi: 10.1186/s12872-020-01497-y. PMID 32493217